Adial Pharmaceuticals Inc [NASDAQ: ADIL] gained 4.67% on the last trading session, reaching $7680000.0 price per share at the time.
Adial Pharmaceuticals Inc represents 15.78 million in outstanding shares, while the company has a total market value of $4.99 million with the latest information. ADIL stock price has been found in the range of $0.2715 to $0.3997.
If compared to the average trading volume of 7.68M shares, ADIL reached a trading volume of 13429387 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adial Pharmaceuticals Inc [ADIL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADIL shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADIL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Rodman & Renshaw have made an estimate for Adial Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 14, 2024. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on October 30, 2018, representing the official price target for Adial Pharmaceuticals Inc stock.
The Price to Book ratio for the last quarter was 0.99, with the Price to Cash per share for the same quarter was set at 0.15.
Trading performance analysis for ADIL stock
Adial Pharmaceuticals Inc [ADIL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 37.94. With this latest performance, ADIL shares dropped by -53.82% in over the last four-week period, additionally sinking by -69.88% over the last 6 months – not to mention a drop of -68.68% in the past year of trading.
Adial Pharmaceuticals Inc [ADIL]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -176.60%, with Return on Assets sitting at -176.60%.
An analysis of Institutional ownership at Adial Pharmaceuticals Inc [ADIL]
There are presently around $3.64%, or 3.77%% of ADIL stock, in the hands of institutional investors. The top three institutional holders of ADIL stocks are: UBS GROUP AG with ownership of 83605.0 shares, which is approximately 1.9988%. MANCHESTER CAPITAL MANAGEMENT LLC, holding 48097.0 shares of the stock with an approximate value of $$55312.0 in ADIL stocks shares; and MANCHESTER CAPITAL MANAGEMENT LLC, currently with $$39498.0 in ADIL stock with ownership which is approximately 0.8211%.
